Close
Achema

DFE Pharma expands its inhalation portfolio with the launch of Lactohale® 400

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1...

DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, announced the expansion of its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale® 400.

The addition of Lactohale® 400 further enhances the completeness of DFE Pharma’s portfolio of inhalation grade lactose. As the whole Lactohale® brand, this new grade can be customized to meet any specific need of pharmaceutical companies and can be developed jointly with formulators to ensure exactly the right outcomes for patients.

The comprehensive range of lactose-based excipients by DFE Pharma, is designed to offer the right characteristics for the full variety of inhaled medicines in the market. For those therapies in development, DFE Pharma works together with R&D teams of pharmaceutical companies, to find the most appropriate formulation for each molecule and device combination.

Lactohale® 400 is a milled, anhydrous lactose grade, that can be used in DPI applications where a relatively good flow with some cohesiveness is required. The anhydrous nature of Lactohale® 400 differentiates it from the most commonly used lactose carriers in DPI formulations. It can provide a different aerosolization performance than lactose monohydrate with the same particle size.

“As codevelopers of Dry Powder Inhalation (DPI), DFE Pharma has a long heritage and great expertise in excipients for inhalation, while we continuously innovate in new premium solutions for inhaled therapies,” said Martti Hedman, CEO of DFE Pharma, “With Lactohale® 400, DFE Pharma expands its comprehensive lactose-based portfolio, designed to offer optimized excipients to match the increasing range of inhalant devices, each with different performance characteristics”.

Latest stories

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back